In 2021, there were new developments in disulfiram, an FDA-approved targeted drug for NETs and pyroptosis, which inhibited septic neutrophil GSDMD activation and reduced NET release, thereby improving sepsis-induced organ damage and survival in septic mice (28). The gene discussed is GSDMD; the disease is Sepsis.